Serum Institute seeks emergency authorisation for Covishield vaccine

The Serum Institute of India has become the first Indian company to seek emergency use authorization for the Oxford Covid vaccine in India.

The move comes a day after Pfizer sought approval from the Drugs Controller General of India for emergency use of its vaccine in the country.

Serum Institute of India tued up with AstraZeneca Plc to conduct trials on its Covishield vaccine in India. 

Sources say the benefit-to-risk ratio strongly supports the widespread use of Covishield as the vaccine is safe and well-tolerated, and can be used effectively for prevention of COVID-19 in the targeted population.

The move comes a day after Pfizer sought approval from the Drugs Controller General of India for emergency use of its vaccine in the country.

Serum Institute of India tued up with AstraZeneca Plc to conduct trials on its Covishield vaccine in India. 

Sources say the benefit-to-risk ratio strongly supports the widespread use of Covishield as the vaccine is safe and well-tolerated, and can be used effectively for prevention of COVID-19 in the targeted population.

While at least five pharmaceutical companies of India are engaged in vaccine development, Serum Institute in Pune has been chosen for mass production of Covishield vaccine developed by Oxford–Astra Zeneca. 

The vaccine manufacturer has completed phase-3 human trials, with the Serum Institute of India announcing last week that the Covishield vaccine is "safe and immunogenic".

While at least five pharmaceutical companies of India are engaged in vaccine development, Serum Institute in Pune has been chosen for mass production of Covishield vaccine developed by Oxford–Astra Zeneca. 

The vaccine manufacturer has completed phase-3 human trials, with the Serum Institute of India announcing last week that the Covishield vaccine is "safe and immunogenic".